We work every day to give you and your patients the best Wearable Cardioverter Defibrillator (WCD) experience so that you can focus on better outcomes. Our push for continued innovation never stops. Explore all the reasons to choose LifeVest:
Peer Reviewed Evidence.
Better Outcomes.
With 20+ years of clinical evidence, LifeVest is the ONLY WCD proven to reduce mortality in a randomized controlled trial (RCT).
75%
REDUCTION
in mortality at 90 days in patients who wore LifeVest.1
90%
ONE-YEAR SURVIVAL
in patients who experience ventricular tachycardia/
AI-Enhanced Algorithm:
Advanced Arrhythmia Discrimination (AArD)
With AArD, the majority of LifeVest patients experience
ZERO
FALSE
ALARMS
AT 90 DAYS3
Starting in 2018, ZOLL has used AI-based AArD technology to filter out non-physiological electrocardiogram (ECG) signals, reducing an already low rate of false alarms. Research published in 2023 validates LifeVest is smarter than ever.
View the data on 96,000 patients >
ECG Classifier:
See Actionable Arrhythmias
Developed with machine learning, LifeVest ECG Classifier filters out noise and identifies arrhythmias that may require intervention — from ablation to implantable cardioverter defibrillator (ICD).
1 IN 14
PATIENTS
experience an actionable arrhythmia during LifeVest use.4
HIGHLY ACCURATE,
FDA-APPROVED
CLASSIFICATION OF ECGs
that may require clinical intervention.5
Patient Engagement App:
Education, Data, & Support During Recovery
The LifeVest Patient App helps patients get the most out of their LifeVest experience.
Trusted Support:
The Largest, Most Experienced WCD Support Team
Trust your patients with the
team that has supported
1M+ LIFEVEST PATIENTS
Your patients have access to in-person representatives with extensive care experience, and a reliable, multilingual support team that can be reached 24/7.
Access for All: Broadest WCD Coverage + Options for Uninsured
For 20+ years, ZOLL has built positive payer relationships, turnkey authorization procedures, and access programs. Trust ZOLL to minimize reimbursement hiccups.
Talk to a product expert to review your patients' options >
Contact your ZOLL Cardiac Management Solutions representative.
Learn more about how 20+ years of continued innovation, experience, and proven results makes LifeVest the WCD solution you can count on.
References
- Olgin JE, Lee BK, Vittinghoff E, et al. Impact of wearable cardioverter-defibrillator compliance on outcomes in the VEST trial: As-treated and per-protocol analyses. J Cardiovasc Electrophysiol 2020;1–10. https://doi.org/10.1111/jce.14404
- Kutyifa V, Moss A, Klein H, et al. One-year follow-up of the prospective registry of patients using the wearable defibrillator (WEARIT-II Registry). Pacing Clin Electrophysiol. 2018;1–7. https://doi.org/10.1111/pace.13448
- Arkles J, Delaughter C, D’Souza B. A novel artificial intelligence based algorithm to reduce wearable cardioverter-defibrillator alarms. J Interv Cardiac Electrophysiol. 2023. https://doi.org/10.1007/s10840-023-01497-w
- Pre-clinical test data on file at ZOLL as of July 2020.
- Kutyifa V, Moss A J, Klein H, et al. Use of the wearable cardioverter defibrillator in high-risk cardiac patients: Data from the prospective registry of patients using the wearable cardioverter defibrillator (WEARIT-II Registry). Circulation 2015;132(17):1613–1619.